Immunovant Operating Income

The latest operating income for IMVT is $-420M as of March 2026. That compares with $6.7M in the prior-year period — down 6345.0% year over year. Investors often review this figure alongside Immunovant's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMVT's operating income moved from $6.7M to $-420M — a 6345.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Immunovant's operating scale or balance-sheet position.

A operating income figure of $-420M for IMVT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IMVT's operating income ($-420M), review year-over-year change from $6.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Immunovant's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.